Halozyme Therapeutics reported $-60.68M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.68B 65M Sep/2026
Baxter International USD 314M 38M Sep/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Cytokinetics USD -167.09M 12.08M Sep/2026
DBV Technologies USD -64.8M 16.9M Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
MannKind USD -59.44M 8.79M Sep/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Pfizer USD 662M 5M Sep/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
United Therapeutics USD 241.3M 89.5M Sep/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024